Friends of Cancer Research FOCR 30 Year Anniversary FOCR 30 Year Anniversary Search
Close

Category: Friends Project Pulse

Project Pulse | Modernizing Tumor Assessment: Integrating AI into Oncology Clinical Trials

 | 

Friends of Cancer Research (Friends) convened a multidisciplinary working group to examine how to incorporate artificial intelligence (AI) into tumor assessment workflows in oncology clinical trials. The group developed a white paper exploring the potential of emerging AI-enabled tools to enhance tumor assessment, as well as key considerations for the adoption and regulatory approval of AI-enabled imaging endpoints that…

Project Pulse | Evaluating AI Agreement in HER2 Assessment Using Whole-Slide Imaging: Insights from the Digital PATH Project

 | 

Biomarkers play a key role in identifying which patients are most likely to benefit from specific therapies, and advances in digital pathology and artificial intelligence (AI) are beginning to reshape how those biomarkers are assessed. Scientists use assays, or tests to assess biomarkers. Outputs from different assays may provide different results, which could impact the…

Project Pulse | The Latest ctMoniTR Publication: Findings and Implications

 | 

This blog post provides an overview of a recent ctMoniTR publication from Friends. A graphical abstract below summarizes the manuscript’s approach, findings, and context. Background  In oncology clinical trials, the gold standard approach for measuring efficacy of cancer therapies is by determining overall survival (OS), or the length of time a patient lives after starting…

Project Pulse | ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials | CCR

 | 

Friends’ recent circulating tumor DNA (ctDNA) study examined 8 clinical trials including 940 patients with advanced non-small cell lung cancer (aNSCLC) treated with tyrosine kinase inhibitors (TKI) to assess whether changes in ctDNA levels could serve as an early indicator of overall survival (OS) and progression-free survival (PFS). The study investigated the association between ctDNA…

Project Pulse | Insights from the Digital PATH Project: HER2 Biomarker Variability Across Artificial Intelligence Models | SABCS

 | 

Friends’ recent research on homologous recombination deficiency (HRD) involved a comparative analysis of 20 independent HRD assays, assessing both an In Silico (n=348; TCGA database) and a Clinical dataset (n=90; nucleic acids from freshly extracted archival ovarian cancer tumor samples). The assays measured a variety of outputs to define DNA damage repair dysfunction and identify patients with high-grade serous ovarian carcinoma (HGSOC) who had HRD. This is important because patients with HRD may benefit from DNA damage repair inhibitor treatments like Poly ADP-ribose Polymerase Inhibitors (PARPi).

Project Pulse | Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology

 | 

Friends of Cancer Research (Friends) is pleased to announce the publication of our new perspective on the significance of pragmatic clinical trials (PCTs) in ESMO Real World Data and Digital Oncology. PCTs evaluate the effectiveness of interventions in settings that more closely resemble real-world care, aiming to produce evidence directly applicable to clinical practice. Recognizing…

Friends’ Project Pulse | Digital PATH Project looks to the future of oncology

 | 

Digital and computational pathology platforms have the potential to provide more precise and novel diagnostic insights to inform treatment decision making and, ultimately, improve patient outcomes. Friends of Cancer Research (Friends) is leading a new research partnership, the Digital and Computational Pathology Tool Harmonization (Digital PATH) Project, to support robust development of digital and computational pathology platforms for use in oncology drug development.

Friends’ Project Pulse | Critical Findings from Friends HRD Harmonization Project

 | 

Homologous Recombination Deficiency (HRD) is a complex biomarker that can help identify patients likely to respond to certain therapies. Friends of Cancer Research’s (Friends) HRD Harmonization Project Harmonization Project is a unique research partnership to find alignment among different assays that measure HRD, to support its use as a biomarker in clinical research and care, and to serve as a foundational…

Friends’ Project Pulse | rw-Response Pilot Moves Forward with Meeting During ASCO

 | 

During the American Society of Clinical Oncology (ASCO) Annual Meeting in June, Friends of Cancer Research (Friends) convened rw-Response Pilot participants to discuss initial findings. This pilot expands on Friends’ previous real-world evidence (RWE) work focused on answering the question: “What real-world endpoints can be evaluated and compared across multiple data sources using a common…

Friends’ Project Pulse | Dose Optimization in Oncology

 | 

  Each year, the Friends of Cancer Research (Friends) Annual Meeting addresses critical issues in oncology drug development and features experts proposing unique approaches to overcoming current challenges. On Day 2 of the Friends Annual Meeting 2021, panelists will focus on the pressing need for improved dose-finding studies in oncology drug development and discuss proposals…